Skip to main content

Table 2 Maximal treatment response

From: Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice

  IRD (N = 127) RD (N = 217) p1
Maximal treatment response, n (%) n = 126 n = 216  
sCR 2 (1.6%) 0.095
CR 12 (9.5%) 19 (8.8%)
VGPR 28 (22.2%) 30 (13.9%)
PR 50 (39.7%) 94 (43.5%)
MR 11 (8.7%) 34 (15.7%)
SD 13 (10.3%) 17 (7.9%)
PD 10 (7.9%) 22 (10.2%)
VGPR+ a 42 (33.3%) 49 (22.7%) 0.042
ORRb 92 (73.0%) 143 (66.2%) 0.227
CBRc 103 (81.7%) 177 (81.9%) 1.000
  1. a VGPR+ − patients reaching at least very good partial response
  2. b ORR – Overall Response Rate (PR or better)
  3. c CBR – Clinical Benefit Rate (MR or better)
  4. 1 p-value of Fisher’s exact test